Extrapulmonary Small Cell Carcinoma Relapse Patterns from Two Cancer Centers

159 patient records from a retrospective review of extrapulmonary small cell carcinoma outcomes. The data includes stage at presentation, treatments, sites of relapse, and survival metrics. It originates from two major cancer centers.

Use Cases

• Analyze progression-free survival and overall survival outcomes by primary site categories like genitourinary or gynaecological.
• Investigate patterns of relapse, such as the prevalence of liver metastases versus rare brain metastases, across patient cohorts.
• Model the relationship between first-line chemotherapy regimens, particularly platinum-based treatments, and overall survival.
• Evaluate the impact of metastatic versus non-metastatic disease presentation on median survival times of 7.6 and 19.5 months respectively.

Strengths

• Data comprises 159 patient records, described as one of the largest datasets for this rare cancer type.
• Includes detailed clinical outcome measures such as response rate (48%), relapse rates (55.9%), and median overall survival (13.4 months).
• Captures treatment specifics, with 80.5% of first-line chemotherapy being platinum-based.

Limitations

• Retrospective study design from two centers may limit generalizability and introduce selection bias.
• Sample size of 159 patients is modest for detailed subgroup analyses across multiple primary sites.
• Data is static from a 2020 publication and may not reflect current treatment protocols.

Provenance

Source

Retrospective review from two major cancer centers.

Collection Method

Retrospective identification of consecutive patients with a histopathological diagnosis.

Freshness

Last updated 2020-06-24.